Table 3.
Systemic Immunomodulatory therapy (IMT) including non-biologic and biologic agents prescribed in our cohort.
| Systemic IMT | Cohort total N = 134 |
JIA N = 64 |
Undifferentiated N = 33 |
Other N = 37 |
|
|---|---|---|---|---|---|
| Non-biologics # (%) | 94 (70%) | 62 (46%) | 13 (10%) | 19 (14%) | |
| Biologics # (%) | 55 (41%) | 39 (29%) | 6 (4%) | 10 (7.5%) | |
| # (%) | Adalimumab (Humira®) | 45 (33.5%) | 26 (19%) | 4 (3%) | 6 (4%) |
| # (%) | Infliximab (Remicade®) | 26 (20%) | 9 (7%) | 2 (1.5%) | 3 (2%) |
| # (%) | Tocilizumab (Actemra®) | 2 (1.5%) | 2 (1.5%) | 0 | 1 (0.7%) |
| # (%) | Abatacept (Orencia®) | 2 (1.5%) | 2 (1.5%) | 0 | 0 |
JIA juvenile idiopathic arthritis.